Watch Ticker

Mineralys Therapeutics, Inc. Common Stock

Go to Mineralys Therapeutics, Inc. Common Stock Website

$13.41

0.00 (0.00%)

Live

Previous Close

$13.41

Day Range

$0 - $0

Previous Day Range

$12.8612 - $13.57

Market Cap

$849.2 million USD

Day Vol.

Previous Day Vol.

600215

Currency

USD

Primary Exchange

Nasdaq

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administere...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Mineralys Therapeutics - Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Mineralys Therapeutics announced positive results from the Phase 3 Launch-HTN trial of its drug lorundrostat for the treatment of uncontrolled or resistant hypertension. The trial demonstrated clinically meaningful and sustained reductions in systolic blood pressure with a favorable safety profile.

Related tickers: MLYS.

Read Full Article

N/A - Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics announced positive results from the Advance-HTN trial, which evaluated the efficacy and safety of their drug lorundrostat in patients with uncontrolled or resistant hypertension. The 50 mg dose of lorundrostat demonstrated a significant reduction in 24-hour ambulatory blood pressure, with a favorable safety profile.

Related tickers: MLYS.

Read Full Article

Trending Tickers

Please sign in to view